

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010350

International filing date: 28 March 2005 (28.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/557,571  
Filing date: 30 March 2004 (30.03.2004)

Date of receipt at the International Bureau: 29 April 2005 (29.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1310359

## THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 19, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/557,571

FILING DATE: *March 30, 2004*RELATED PCT APPLICATION NUMBER: *PCT/US05/10350*

Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

**"EXPRESS MAIL CERTIFICATE"****"Express Mail" Mailing Label Number EV332943715US****Date Of Deposit: March 30, 2004**

I Hereby Certify That This Paper Or Fee Is Being Deposited With The United States Postal Service "Express Mail Post Office To Addressee" Service Under 37 CFR 1.10 On The Date Indicated Above And Is Addressed To: COMMISSIONER FOR PATENTS, MAIL STOP: PROVISIONAL APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

**Name Of Person Mailing Paper Or Fee**

(Type Or Print) Diane Halata  
 Signature Diane B. Halata

22154 U.S.PTO  
60/557571

**PROVISIONAL APPLICATION COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION for PATENT under 37 CFR 1.53(c).

Docket No.	PB60811P		
------------	----------	--	--

INVENTOR(s) / APPLICANT(s)			Residence (City and Either State or Foreign Country)
Last Name	First Name	Middle Initial	
ANDRONIS	Vlassios		Wayne, Pennsylvania
PATEL	Kamlesh	H.	King of Prussia, Pennsylvania

TITLE OF THE INVENTION (280 characters max)					
Correspondence Address:				NOVEL COMPOSITIONS	
GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 709 Swedeland Road King of Prussia				Telephone No. 610-270-5044 Facsimile No. 610-270-5090	
State	PA	Zip Code	19406-0939	Country	United States of America

ENCLOSED APPLICATION PARTS (check all that apply)			Total Number of Pages = 16
<input checked="" type="checkbox"/> Specification	Number of Pages	15	
<input checked="" type="checkbox"/> Abstract	Number of Pages	1	<input type="checkbox"/> Other (specify)
<input type="checkbox"/> Drawings	Number of Sheets		

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 19-2570	PROVISIONAL FILING FEE AMOUNT (\$)	\$160.00

Respectfully submitted,  
 Signature:

Nora Stein-Fernandez Date: March 30, 2004  
 Nora Stein-Fernandez Registration No.: 36,689

Additional inventors are being named on separately numbered sheets attached hereto.

**PROVISIONAL APPLICATION FILING ONLY**

SEND TO: Commissioner for Patents, P.O. Box 1450, Mail Stop: Patent Application, Alexandria, VA 22313-1450.

20462

CUSTOMER NUMBER

Novel Compositions

The present invention relates to novel compositions containing the NK3 receptor antagonist talnetant [(S)-(-)-N-( $\alpha$ -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide] which compositions have enhanced bioavailability. In addition, the invention relates to processes for the preparation and to uses of the compositions in therapy.

Talnetant, its preparation and its use in the treatment of pulmonary disorders, disorders of the central nervous system and neurodegenerative disorders are disclosed in published International Patent application WO 95/32948. Published International Patent applications WO 97/19927, WO 97/19928, WO 99/14196 and WO 02/094187 disclose additional therapeutic utilities for talnetant, pharmaceutically acceptable salts and processes for its preparation. The above-mentioned patent applications are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Talnetant has low aqueous solubility (approximately 0.03 mg/mL at pH 1 and 0.001 mg/ml, at pH 7.0). Typically drugs with low aqueous solubility are absorbed slowly across the walls of the gastrointestinal tract (GIT) due to poor dissolution of the solid in the GIT leading to a small diffusive driving force.

There are a number of different methods employed to improve absorption of a particular drug substance. It may be possible to develop so-called prodrugs or salts of the active agent, i.e. more soluble derivatives, by attaching a solubilizing group (e.g. phosphate, succinate or polyethylene glycol) to the drug, thereby taking advantage of the high solubility and dissolution rate of the derivative prodrug/salt. Alternatively, it is known to use physical formulation methods, such as use of amorphous drug or dispersion in a soluble carrier to increase the dissolution rate of the drug product and hence the absorption rate (J.H. Fincher, *J. Pharm. Sci.*, 1968, 57, 1825 and G.L. Amidon *et al.*, *J. Pharm. Sci.*, 1980, 12, 1363).

A further alternative is to decrease the particle size of the drug. Decreasing the particle size increases the surface area of the drug particle, thereby increasing its dissolution rate.

- 5 A variety of processes have been developed to prepare particles of drug substance. Typically, dry milling techniques are used for the preparation of particulate medicaments (see E.L. Parrott, *J. Pharm. Sci.*, 1974, 63, 813). Air jet milling and fluid energy milling (micronising) have been favoured because of the reduced risk of introducing contamination from mill materials. More recently, particles having a
- 10 size of less than 1 µm have been obtained using wet milling processes. For example, EP 0 262 560 describes the use of wet milling techniques to prepare compositions containing benzoyl urea derivatives in which the average particle size is 1 µm or less. Provision of the fine particles is said to improve the absorbability of the poorly water soluble benzoyl urea compounds in the GIT thereby increasing
- 15 their bioavailability. European Patent Number EP 0 499 299 B1 describes a wet milling procedure for preparing particles of a crystalline drug substance, which particles have a surface modifier adsorbed on the surface in an amount sufficient to maintain an 'effective average particle size' of less than about 400 nm.
- 20 Aqueous dispersions obtained from wet milling processes may be used directly as a therapeutic agent if prepared under conditions of appropriate hygiene, for example, by using water and other components which meet Ph Eur/USP standards. For the preparation of formulations for use in human therapy, it is preferred that the aqueous dispersion is converted to a dried powder. This is suitably carried out by
- 25 spray drying the resulting aqueous dispersion, typically collecting the product from the dryer using a cyclone separator. The resulting aqueous dispersion may also be spray granulated.

The objective of spray drying is to remove water from dispersions of drug particles

- 30 so that the powder can be processed further to prepare capsule or tablet or other suitable oral dosage form. However, it is critical that particles obtained after spray drying are substantially the same size when dispersed in aqueous medium as the freshly-milled particles. If spray dried particles of the same size as the freshly-milled particles are obtained, it is referred in the art (and hereinafter) as complete
- 35 "recovery of particle size".

However, we have found that spray drying certain wet-milled dispersions of talnetant results in a poor recovery of particle size, i.e. a significant increase in particle size is seen when the spray dried particles are added to aqueous media.

5

We have surprisingly discovered that spray drying wet-milled dispersions of talnetant containing a suitable excipient addresses this problem, resulting in increased recovery of particle size.

10 According to a first aspect, the invention provides a process for the preparation of a spray-dried composition, the composition comprising a) talnetant particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$  and b) one or more ionic surfactants, the process comprising a) wet milling a dispersion of solid particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , containing one or more ionic surfactant, then b) spray 15 drying or spray granulating the resulting dispersion.

As used herein, the term  $D_{v90}$  means that no less than 90% of the particles have a volume mean diameter of  $D_v$ . Similarly  $D_{v50}$  and  $D_{v10}$  means that not less than 50% and 10% respectively have a volume mean diameter of  $D_v$ .

20

As used herein with reference to particle size, the term "volume mean diameter" ( $D_v$ ) means,

$$D_v = \sqrt[3]{\frac{\sum nD^3}{\sum n}}$$

25 where,  $n$  is the number of particles and  $D$  is the diameter of the particles, in accordance with, E. L. Parrott., "Milling", Chapter 2, *The Theory and Practice of Industrial Pharmacy*, Ed. Lachman et al., Third Edition, 1986, page 26.

30 Talnetant may be wet-milled in any suitable aqueous, non-aqueous or organic solvent (e.g. an oil). Preferably talnetant is wet-milled in an aqueous solvent.

Preferably the dispersion contains 5 to 50 % w/w of talnetant, more preferably 15 to 30 % w/w.

According to a second aspect, the invention provides a spray dried pharmaceutical composition comprising a) talnetant particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , and b) one or more ionic surfactants.

5 We have surprisingly discovered that a spray-dried pharmaceutical composition according to the second aspect greatly improves bioavailability.

Preferred ionic surfactants are sodium lauryl sulfate and dioctyl sodium sulfosuccinate (docusate sodium). A particularly preferred surfactant is sodium lauryl sulfate.

Preferably the concentration of surfactant in the spray dried composition is 0.5 to 3.0% by weight of talnetant. Preferably the concentration of surfactant in the dispersion prior to spray drying is 0.05 to 5% by weight of dispersion, more 15 preferably 0.05 to 2%.

Preferably the spray-dried composition comprises one or more anti-agglomeration agents (for example polyvinyl pyrrolidone (PVP) or Povidone, hydroxypropyl methyl cellulose and hydroxyethyl cellulose and hydroxypropylcellulose). Preferably the 20 concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant. Preferably the concentration of anti-agglomeration agent in the dispersion prior to spray drying is 0.1 to 10.0% by weight of dispersion, more preferably 0.5 to 5.0%.

25 Preferably the spray dried composition comprises one or more carriers (for example mannitol, sorbitol, lactose, lacitol, xylitol and starch). Preferably the concentration of the carrier in the spray dried composition is 10 to 50 % by weight of talnetant. Preferably the concentration of the carrier in the dispersion prior to spray drying is 0.1 to 30% by weight of dispersion, more preferably 5 to 15%.

30 The spray-dried composition and dispersion prior to spray drying may contain further suitable pharmaceutically acceptable excipients. Suitable excipients are described in the *Handbook of Pharmaceutical Excipients*, Pharmaceutical Press, 1986, published by The American Pharmaceutical Association and The Royal

Pharmaceutical Society of Great Britain. Examples of further excipients include stabilisers to maintain the particles in suspension.

The spray dried composition may be administered to the subject without further processing, however it will generally be formulated into other dosage forms in conjunction with further pharmaceutically acceptable excipients selected with regard to the desired dosage form. These further excipients will typically be added to the spray dried composition after spray drying.

5 Preferably the dosage form is administered orally. Oral administration will typically involve swallowing so that the compound enters the GIT. Dosage forms for oral administration include solid formulations such as tablets, capsules containing particulates or powders, sachets, vials, powders, granules, lozenges, reconstitutable powders and liquid preparations (such as suspensions, emulsions

10 and elixirs).

15 Oral dosage forms may contain further excipients such as binding agents (for example syrup, acacia, gelatin, sorbitol, starch, PVP, HPMC, and tragacanth); fillers (for example lactose, sugar, maize-starch, calcium phosphate, sorbitol and glycine);

20 tabletting lubricants (for example magnesium stearate); and disintegrants (for example starch, sodium starch glycollate and microcrystalline cellulose). In addition, the oral dosage form may contain preservatives, anti-oxidant, flavours, granulation binders, wetting agents and colourants.

25 Preferably the dosage form for oral administration is a tablet. Tablets may be prepared using standard technology familiar to the formulation chemist, for example by direct compression, granulation, melt congealing and extrusion. The tablet may be coated or uncoated. The tablet may be formulated to be immediate or controlled release. Controlled release formulations include delayed-, sustained-, pulsed or

30 dual-release. Suitable tabletting excipients are described in the *Handbook of Pharmaceutical Excipients*, Pharmaceutical Press, 1986, published by The American Pharmaceutical Association and The Royal Pharmaceutical Society of Great Britain. Typical tabletting excipients include: carriers (for example lactose and starch), lubricating agents (for example magnesium stearate), binding agents,

wetting agents, colorants, flavourings, glidants and disintegrants (for example croscarmellose sodium).

The composition of a preferred tablet according to the invention is Tablet A  
5 described hereinafter in Example 2.

Excipients suitable for preparing liquid dosage forms include: suspending agents (for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel and hydrogenated edible fats);  
10 emulsifying agents (for example lecithin, sorbitan monooleate and acacia); aqueous or non-aqueous vehicles, which include edible oils (for example almond oil and fractionated coconut oil), oily esters (for example esters of glycerine and propylene glycol), ethyl alcohol, glycerine, water and normal saline; preservatives (for example methyl, propyl p-hydroxybenzoate and sorbic acid); and if desired  
15 conventional flavouring or colouring agents.

The effective dose of talnetant depends on the condition of the patient, the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg of talnetant, preferably 30 to 500 mg, most preferably 200 or 400 mg. The  
20 unit dose may be administered one or more times per day (for example 2, 3 or 4 times per day). The total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.

25 The compositions and tablets of the invention are preferably adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.

30 NK3 receptor antagonists, including talnetant, are useful in the treatment and prevention of a wide variety of clinical diseases and conditions characterised by overstimulation of the NK3 receptors. These diseases and conditions (hereinafter referred to as "diseases and conditions of the invention") include: CNS disorders  
35 such as depression (which term includes bipolar (manic) depression (including type

I and type II), unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features (e.g. lethargy, over-eating/obesity, hypersomnia) or postpartum onset, seasonal affective disorder and dysthymia, depression-related anxiety, psychotic depression, and depressive disorders resulting from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion); anxiety disorders (including generalised anxiety disorder (GAD), social anxiety disorder (SAD), agitation, tension, social or emotional withdrawal in psychotic patients, panic disorder, and obsessive compulsive disorder); phobias (including agoraphobia and social phobia); psychosis and psychotic disorders (including schizophrenia, schizo-affective disorder, schizophreniform diseases, acute psychosis, alcohol psychosis, autism, delerium, mania (including acute mania), manic depressive psychosis, hallucination, endogenous psychosis, organic psychosyndrome, paranoid and delusional disorders, puerperal psychosis, and psychosis associated with neurodegenerative diseases such as Alzheimer's disease); post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD); cognitive impairment (e.g. the treatment of impairment of cognitive functions including attention, orientation, memory (memory disorders, amnesia, amnesic disorders and age-associated memory impairment) and language function, and including cognitive impairment as a result of stroke, Alzheimer's disease, Aids-related dementia or other dementia states, as well as other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states)); convulsive disorders such as epilepsy (which includes simple partial seizures, complex partial seizures, secondary generalised seizures, generalised seizures including absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic clonic seizures and atonic seizures); psychosexual dysfunction (including inhibited sexual desire (low libido), inhibited sexual arousal or excitement, orgasm dysfunction, inhibited female orgasm and inhibited male orgasm, hypoactive sexual desire disorder (HSDD), female sexual desire disorder (FSDD), and sexual dysfunction side-effects induced by treatment with antidepressants of the SSRI-class); sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy); disorders of eating behaviours (including anorexia nervosa and bulimia nervosa); neurodegenerative diseases (such as Alzheimer's disease, ALS, motor neuron disease and other motor disorders such as Parkinson's disease (including relief

from locomotor deficits and/or motor disability, including slowly increasing disability in purposeful movement, tremors, bradykinesia, hyperkinesia (moderate and severe), akinesia, rigidity, disturbance of balance and co-ordination, and a disturbance of posture), dementia in Parkinson's disease, dementia in Huntington's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like, and demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis); withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities (such as abuse of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine and phencyclidine-like compounds, opiates such as cannabis, heroin, morphine, sedative, hypnotic, amphetamine or amphetamine-related drugs such as dextroamphetamine, methylamphetamine or a combination thereof); pain (which includes neuropathic pain (including diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; pain associated with fibromyalgia or cancer; AIDS-related and HIV-related neuropathy; chemotherapy-induced neuropathy; neuralgia, such as post-herpetic neuralgia and trigeminal neuralgia; sympathetically maintained pain and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions such as rheumatoid arthritis and osteoarthritis; reflex sympathetic dystrophy such as shoulder/hand syndrome), acute pain (e.g. musculoskeletal pain, post operative pain and surgical pain), inflammatory pain and chronic pain, pain associated with normally non-painful sensations such as "pins and needles" (paraesthesia and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia), pain associated with migraine, and non-cardiac chest pain); certain CNS-mediated disorders (such as emesis, irritable bowel syndrome and non-ulcer dyspepsia); and pulmonary disorders (such as asthma, chronic obstructive pulmonary disease (COPD), airway hyperreactivity and cough).

More preferred diseases or conditions (hereinafter referred to as "preferred diseases and conditions of the invention") mediated by modulation of the NK3 receptor are depression; anxiety disorders; phobias; psychosis and psychotic

disorders; post-traumatic stress disorder; attention deficit hyperactive disorder (ADHD); withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities; irritable bowel syndrome; cognitive impairment; convulsive disorders; psychosexual dysfunction; sleep disorders;

5      disorders of eating behaviours; neurodegenerative diseases; pain; emesis; irritable bowel syndrome; non-ulcer dyspepsia; and pulmonary disorders (such as asthma, chronic obstructive pulmonary disease (COPD), airway hyperreactivity and cough).

10      No unacceptable toxicological effects were seen when the compositions of the invention were administered.

Suitable milling apparatus for the preparation of a compositions according to the present invention include, conventional wet bead mills such as those manufactured by Nylacast, NETZSCH, DRAIS and others. Suitably, the milling chamber of said 15      milling apparatus is lined with or constructed from an abrasion-resistant polymer material. Preferably, the milling chamber of said milling apparatus is lined with or constructed from nylon. An example of a suitable milling chamber is described in International Patent Application, Publication Number WO 02/00196.

20      Suitable grinding media for use in the preparation of a pharmaceutical composition according to the present invention include glass beads and ceramic beads, for example, those made from rare earth oxide materials. The diameter of said grinding media is suitably within the range 0.1 mm to 3 mm, and is preferably within the range 0.3 mm to 0.8 mm. The density of said grinding media is suitably greater 25      than 3 gcm<sup>-3</sup>, and is preferably within the range 5 to 10 gcm<sup>-3</sup>.

Suitable spray drying and spray granulating techniques will be apparent to those skilled in the art (see for example, Gilbert S. Bunker, "Modern Pharmaceutics, Drugs and the Pharmaceutical Sciences", 1996 and references cited therein) and 30      may be effected using a spray dryer, such as the Niro SD 6.3R Spray Dryer, Mobile Minor Niro or a Yamato GA-32 Spray Dryer, or a fluid bed granulator, such as Glatt fluid bed granulator.

35      Particles prepared according to the present invention may be sized using conventional techniques known in the art, such as laser light diffraction and photon

correlation spectroscopy. A suitable particle sizing apparatus is the Malvern Mastersizer. The Malvern Mastersizer and its operation will be familiar to the skilled person with reference to its operating manual.

5

The following Examples illustrate the present invention.

Example 1

Preparation of spray dried compositions and particle-size recovery after dissolution

10 in water

a) Composition according to the invention (Composition 1)

Sodium lauryl sulphate (0.3% w/w), povidone (Kollidone K30) (1.7% w/w) and mannitol powder USP (10.0% w/w) were dissolved in the purified water (68.0% w/w). Solid talnetant (20.0% w/w) was then slowly added with continuous mixing 15 until a homogeneous suspension was obtained. The homogenous suspension was passed through a Netzsch bead mill containing 85% by volume of yttrium-stabilised 0.3 mm zirconium oxide beads. The dispersion was re-circulated with continual mixing until a  $D_{v90}$  of  $>0.4 \mu\text{m}$   $<1.0 \mu\text{m}$  was obtained. The  $D_{v90}$  was measured using Malvern Particle Sizer.

20

This dispersion was spray-dried using a Mobile Minor Niro spray dryer (operated in accordance with the manufacturers instructions) at the following settings: 2 Fluid Nozzle: 2 Bar pressure; Pump Speed: 35 mL/min (suspension spray rate); Inlet Temperature: 150 °C; Outlet Temperature: 60 °C.

25

The spray-dried composition was dispersed in water and the  $D_v$  was measured using a Malvern Particle Sizer.

b) Comparative Example (Composition 2)

30 The procedure and conditions with some modifications to spray drying parameters (outlet temp 110 deg C and outlet temp 40 deg C) as described under a) above was repeated except that the ionic surfactant sodium lauryl sulfate was replaced by pluronic F68 (a non-ionic surfactant). The  $D_{v90}$  after milling was the same as for procedure a).

35

The particle size distribution following redispersion in water for compositions 1 and 2 are shown in Table 1 (The values in parentheses are the corresponding  $D_V$  values before spray drying). The table shows that composition 1 gives a virtually complete recovery of particle size after redispersion in water, whereas composition 5 2 results in substantial agglomeration to give much larger particles.

Table 1

	Composition 1	Composition 2
$D_{V10}$ ( $\mu\text{m}$ )	0.077 (0.080)	0.13 (0.075)
$D_{V50}$ ( $\mu\text{m}$ )	0.179 (0.190)	0.55 (0.177)
$D_{V90}$ ( $\mu\text{m}$ )	0.437 (0.488)	2.75 (0.411)

Example 2

10 Comparative study to evaluate the effect on pK parameters of oral administration of compositions of to conscious, male beagle dogs.

A catheter was placed in the cephalic vein of each of four fasted male beagle dogs. Each dog was administered half a Tablet A, the composition of which is shown in Table 2 (the composition of the invention). Blood samples were collected via the 15 catheter prior to dosing and at the following times after dosing: 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480, 600 and 1440 minutes. Plasma was prepared and stored frozen for analysis. Plasma concentrations of (Limit of quantitation = 10 20 ng/mL) were quantified by an LC/MS/MS method. Noncompartmental analysis was used for pharmacokinetic analysis of plasma concentration versus actual sampling time data. The dogs were fed at 6 hours post-dose (following the collection of the 6-hour blood sample) and food was removed one hour later.

After a wash-out period of one week, the procedure was repeated on the same four dogs with Tablet B. After a further one week wash-out period, the procedure was 25 repeated with Tablet C, and so on with Tablet D. (Tablets B, C and D are comparative examples).

Table 2

Tablet	Constituents (mg/tablet)	Dose (mg/kg)
A	talnetant ( $D_{V90} = 0.5 \mu\text{m}$ (100) Sodium Lauryl Sulfate (1.5) Povidone (Kollidone K30) (8.5) Mannitol (50)	5.46 $\pm$ 0.60 (n=3)

Tablet	Constituents (mg/tablet)	Dose (mg/kg)
	Avicel PH 200 (Microcrystalline Cellulose) (169.4) Crosppovidone (38.70) Colloidal Silicon Dioxide (Cab-O-Sil) (4) Magnesium Stearate (2.9) Opadry yellow 03B12905 (11.25)	
B	Talnetant ( $D_{v90} = 0.5 \mu\text{m}$ (100) Poloxamer 127 (8.5) Povidone (Kollidone K30) (5) Natrosol 250SL (HEC) (10) Avicel PH 200 (Microcrystalline Cellulose) (205.9) Crosppovidone (38.70) Colloidal Silicon Dioxide (Cab-O-Sil) (4) Magnesium Stearate (2.9) Opadry yellow 03B12905 (11.25)	5.09 ± 0.66 (n=4)
C	Talnetant ( $D_{v90} = 0.5 \mu\text{m}$ (100) Poloxamer 188 (20.03) Povidone (Kollidone K30) (10.01) Avicel PH 200 (Microcrystalline Cellulose) (199.36) Crosppovidone (38.70) Colloidal Silicon Dioxide (Cab-O-Sil) (4) Magnesium Stearate (2.9) Opadry yellow 03B12905 (11.25)	5.43 ± 0.76 (n=4)
D	Talnetant ( $D_{v90} = 0.5 \mu\text{m}$ (100) Poloxamer 188 (10) Povidone (Kollidone K30) (10) Avicel PH 200 (Microcrystalline Cellulose) (209.4) Crosppovidone (38.70) Colloidal Silicon Dioxide (Cab-O-Sil) (4) Magnesium Stearate (2.9) Opadry yellow 03B12905 (11.25)	5.49 ± 0.68 (n=4)

The results of the study are shown in Table 3. The results show that administration of Tablet A (the composition of the invention) lead to significant improvement in bioavailability compared with the comparative examples (Tablets B, C and D). In

5 addition the results show that the values for Tablet A were the most consistent among the subjects.

The average relative bioavailability for the three formulations against Tablet C was calculated by determining the relative bioavailability for each animal then calculating  
10 the average and standard deviation of the individual relative bioavailability values. Overall, the average relative bioavailability of Table A was  $1.96 \pm 0.34$ , and the individual values were 1.81, 2.35 and 1.72.

15  $C_{\text{max}}$  is the maximum plasma concentration of achieved.  $T_{\text{max}}$  is the time after administration at which the maximum concentration was achieved. AUC is the Area Under the Curve of a plot of plasma concentration against time. AUC(0-t) refers to

the area from  $t = 0$  to the last quantifiable concentration. AUC (0-360) refers to the area from  $t = 0$  to  $t = 360$  minutes.

Table 3

Tablet	$C_{max}$ ( $\mu\text{g/mL}$ )	$T_{max}$ (min)	AUC (0-360) (min. $\mu\text{g/mL}$ )	AUC (0-t) (min. $\mu\text{g/mL}$ )	Relative Oral Bioavailability $\frac{\text{AUC(0-360)}}{\text{AUC(0-360)_{Tablet C}}}$
A	$4.04 \pm 0.287$	$521.0 \pm 68.4$	$742.1 \pm 55.0$	$3306.0 \pm 117.2$	$1.96 \pm 0.34$
B	$2.20 \pm 0.796$	$480.0 \pm 0.0$	$345.7 \pm 139.2$	$1373.4 \pm 730.3$	$1.03 \pm 0.23$
C	$2.15 \pm 0.669$	$278.3 \pm 307.5$	$336.8 \pm 121.2$	$1654.0 \pm 1354.8$	$1.00 \pm 0.00$
D	$1.94 \pm 0.850$	$419.8 \pm 206.3$	$305.3 \pm 109.8$	$1391.1 \pm 395.7$	$0.94 \pm 0.27$

Claims

1. A process for the preparation of a spray-dried composition, the composition comprising a) talnetant particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$  and  
5 b) one or more ionic surfactants, the process comprising a) wet milling a dispersion of solid particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , containing one or more ionic surfactant, then b) spray drying or spray granulating the resulting dispersion.
- 10 2. A process according to claim 1 wherein talnetant is wet-milled in an aqueous solvent.
- 15 3. A process according to any preceding claim wherein the dispersion contains 5 to 50 % w/w of talnetant.
4. A spray dried pharmaceutical composition comprising a) talnetant particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , and b) one or more ionic surfactants.
- 20 5. A spray dried pharmaceutical composition according to claim 4 wherein the ionic surfactants are sodium lauryl sulfate or dioctyl sodium sulfosuccinate (docusate sodium).
- 25 6. A spray dried pharmaceutical composition according to claim 5 wherein the ionic surfactant is sodium lauryl sulfate.
7. A spray dried pharmaceutical composition according to any one of claims 4 to 6 wherein the concentration of surfactant in the composition is 0.5 to 3.0% by weight of talnetant.
- 30 8. A spray dried pharmaceutical composition according to any one of claims 4 to 7 wherein the composition comprises one or more anti-agglomeration agents (for example polyvinyl pyrrolidone (PVP) or Povidone, hydroxypropyl methyl cellulose and hydroxyethyl cellulose and hydroxypropylcellulose).

9. A spray dried pharmaceutical composition according to claim 8 wherein the concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant.
- 5 10. A spray dried pharmaceutical composition according to any one of claims 4 to 9 wherein the composition comprises one or more carriers (for example mannitol, sorbitol, lactose, lacitol, xylitol and starch).
- 10 11. A spray dried pharmaceutical composition according to claim 10 wherein the concentration of the carrier in the spray dried composition is 10 to 50 % by weight of talnetant.
12. A dosage form comprising a composition defined in any one of claims 4 to 11.
- 15 13. A dosage form according to claim 12 is administered orally.
14. A dosage form according to claim 13 administered as a tablet.

**ABSTRACT**

The present invention relates to novel compositions containing the NK3 receptor antagonist talnetant [(S)-(-)-N-( $\alpha$ -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide] which compositions have enhanced bioavailability. In addition, the invention relates to processes for the preparation and to uses of the compositions in therapy.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number  
WO 2005/097077 A3(51) International Patent Classification<sup>7</sup> : A61K 9/16, 31/47

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/US2005/010350

(22) International Filing Date: 28 March 2005 (28.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/557,571 30 March 2004 (30.03.2004) US(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM CORPORATION  
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDRONIS, Vlasis [GR/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). PAN, Rennan [CN/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). PATEL, Kamlesh, Rameshchandra [US/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agents: STEIN-FERNANDEZ, Nora et al.; Glaxo-SmithKline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
13 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SPRAY DRIED PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention relates to novel compositions containing the NK<sub>1</sub> receptor antagonist talnetant which compositions have enhanced bioavailability. In addition, the invention relates to processes for the preparation and to uses of the compositions in therapy.

# INTERNATIONAL SEARCH REPORT

tional Application No  
'US2005/010350

A. CLASSIFICATION OF SUBJECT MATTER  
A61K9/16 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/094187 A (SMITHKLINE BEECHAM CORPORATION; HAY, DOUGLAS, WILLIAM, PIERRE; SANGER,) 28 November 2002 (2002-11-28) cited in the application page 2, line 3 - line 13; claims page 10, line 3 - line 12 page 11, line 8 - line 15	1-32
A	EP 0 499 299 A (STERLING WINTHROP INC; NANOSYSTEMS L.L.C) 19 August 1992 (1992-08-19) cited in the application page 3, line 19 - line 26 page 4, line 13 - line 15 page 4, line 32 - line 37 page 5, line 19 - line 22 page 5, line 45 - line 46	1-32
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*8\* document member of the same patent family

Date of the actual completion of the international search

21 February 2006

Date of mailing of the International search report

07/03/2006

### Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

### Authorized officer

Marttin, E

**INTERNATIONAL SEARCH REPORT**ional Application No  
US2005/010350**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2002/169181 A1 (PAIRET MICHEL ET AL) 14 November 2002 (2002-11-14) paragraph '0003! paragraph '0008! paragraph '0057! -----	1-32

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
/US2005/010350

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 02094187	A	28-11-2002	BR	0209662 A	20-04-2004	
			CA	2447063 A1	28-11-2002	
			CN	1509175 A	30-06-2004	
			CZ	20033115 A3	15-09-2004	
			EP	1387687 A2	11-02-2004	
			HU	0400966 A2	30-08-2004	
			JP	2004534761 T	18-11-2004	
			MX	PA03010509 A	02-03-2004	
			NO	20035121 A	17-11-2003	
			NZ	529462 A	29-07-2005	
			PL	367308 A1	21-02-2005	
EP 0499299	A	19-08-1992	AT	195416 T	15-09-2000	
			AU	654836 B2	24-11-1994	
			AU	1014792 A	30-07-1992	
			CA	2059432 A1	26-07-1992	
			DE	69231345 D1	21-09-2000	
			DE	69231345 T2	26-04-2001	
			DK	499299 T3	02-01-2001	
			ES	2149164 T3	01-11-2000	
			FI	920321 A	26-07-1992	
			GR	3034759 T3	28-02-2001	
			HU	62462 A2	28-05-1993	
			IE	920217 A1	29-07-1992	
			IL	100754 A	16-10-1996	
			JP	3602546 B2	15-12-2004	
			JP	4295420 A	20-10-1992	
			KR	200061 B1	15-06-1999	
			MX	9200291 A1	01-10-1992	
			NO	920334 A	27-07-1992	
			NZ	241362 A	25-06-1993	
			PT	499299 T	31-01-2001	
			SG	55104 A1	21-12-1998	
			RU	2066553 C1	20-09-1996	
			US	5145684 A	08-09-1992	
			US	5399363 A	21-03-1995	
US 2002169181	A1	14-11-2002	US	2003212075 A1	13-11-2003	

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number  
WO 2005/097077 A2

(51) International Patent Classification<sup>7</sup>: A61K 9/16, 31/47

(21) International Application Number:  
PCT/US2005/010350

(22) International Filing Date: 28 March 2005 (28.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/557,571 30 March 2004 (30.03.2004) US

(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDRONIS, Vlassios [GR/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). PAN, Renian [CN/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). PATEL, Kamlesh, Rameshchandra [US/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agents: STEIN-FERNANDEZ, Nora et al.; GlaxoSmithKline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

## Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

## Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SPRAY DRIED PHARMACEUTICAL COMPOSITIONS

(57) Abstract: The present invention relates to novel compositions containing the NK<sub>1</sub> receptor antagonist talnetant which compositions have enhanced bioavailability. In addition, the invention relates to processes for the preparation and to uses of the compositions in therapy.


WO 2005/097077 A2

15 PGS SPEC

Spray Dried Pharmaceutical Compositions

The present invention relates to novel compositions containing the NK<sub>3</sub> receptor antagonist talnetant which compositions have enhanced bioavailability. In addition, the 5 invention relates to processes for the preparation and to uses of the compositions in therapy.

Talnetant, (S)-(-)-N-( $\alpha$ -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide, (alternatively 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide), 10 has the chemical structure (A).



Talnetant, its preparation and its use in the treatment of pulmonary disorders, 15 disorders of the central nervous system and neurodegenerative disorders are disclosed in published International Patent application WO 95/32948. Published International Patent applications WO 97/19927, WO 97/19928, WO 99/14196 and WO 02/094187 disclose additional therapeutic utilities for talnetant, pharmaceutically acceptable salts and processes for its preparation. The above-mentioned patent 20 applications are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Talnetant has low aqueous solubility (approximately 0.03 mg/ml at pH 1 and 0.001 25 mg/ml, at pH 7.0). Typically drugs with low aqueous solubility are absorbed slowly

across the walls of the gastrointestinal tract (GIT) due to poor dissolution of the solid in the GIT leading to a small diffusive driving force.

There are a number of different methods employed to improve absorption of a particular drug substance. It may be possible to develop so-called prodrugs or salts of the active agent, i.e. more soluble derivatives, by attaching a solubilizing group (e.g. phosphate, succinate or polyethylene glycol) to the drug, thereby taking advantage of the high solubility and dissolution rate of the derivative prodrug/salt. Alternatively, it is known to use physical formulation methods, such as use of amorphous drug or dispersion in a soluble carrier to increase the dissolution rate of the drug product and hence the absorption rate (J.H. Fincher, *J. Pharm. Sci.*, 1968, 57, 1825 and G.L. Amidon *et al.*, *J. Pharm. Sci.*, 1980, 12, 1363).

A further alternative is to decrease the particle size of the drug. Decreasing the particle size increases the surface area of the drug particle, thereby increasing its dissolution rate.

A variety of processes have been developed to prepare fine particles of drug substance. Typically, dry milling techniques are used for the preparation of particulate medicaments (see E.L. Parrott, *J. Pharm. Sci.*, 1974, 63, 813). Air jet milling and fluid energy milling (micronising) have been favoured because of the reduced risk of introducing contamination from mill materials. More recently, particles having a size of less than 1  $\mu\text{m}$  have been obtained using wet milling processes. For example, published European Patent application EP-A-0 262 560 describes the use of wet milling techniques to prepare compositions containing benzoyl urea derivatives in which the average particle size is 1  $\mu\text{m}$  or less. Provision of the fine particles is said to improve the absorbability from the GIT of the poorly water soluble benzoyl urea compounds thereby increasing their bioavailability. Published European Patent application EP-A-0 499 299 describes a wet milling procedure for preparing particles of a crystalline drug substance, which particles have a surface modifier adsorbed on the surface in an amount sufficient to maintain an 'effective average particle size' of less than about 400 nm.

Aqueous dispersions obtained from wet milling processes may be used directly as a therapeutic agent if prepared under conditions of appropriate hygiene, for example, by

using water and other components which meet Ph Eur/USP standards. For the preparation of formulations for use in human therapy, it is preferred that the aqueous dispersion is converted to a dried powder. This is suitably carried out by spray drying the resulting aqueous dispersion, typically collecting the product from the dryer using a 5 cyclone separator. The resulting aqueous dispersion may also be spray granulated.

The objective of spray drying is to remove water from dispersions of drug particles so that the powder can be processed further to prepare capsule or tablet or other suitable oral dosage form. However, it is desirable that particles obtained from the spray dried 10 powder are substantially the same size when dispersed in aqueous medium as the freshly-milled particles. If particles of the same size as the freshly-milled particles are obtained, it is referred to in the art (and hereinafter) as complete "recovery of particle size".

15 However, we have found that spray drying certain wet-milled dispersions of talnetant results in a poor recovery of particle size, i.e. a significant increase in particle size is seen when the spray dried particles are added to aqueous media.

We have discovered that spray drying wet-milled dispersions of talnetant containing 20 suitable excipients addresses this problem, resulting in increased recovery of particle size and greatly improving bioavailability *in vivo*.

According to a first aspect, the invention provides a process for the preparation of a spray-dried composition, the composition comprising i) talnetant particles having a 25  $D_{V90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , ii) one or more ionic surfactant and iii) one or more soluble carrier, the process comprising a) wet milling a dispersion of the solid talnetant particles until the  $D_{V90}$  is in the range from 0.1 to 2.0  $\mu\text{m}$ , which dispersion comprises the one or more ionic surfactant and the one or more soluble carrier, then b) spray drying or spray granulating the resulting dispersion.

30 As used herein, the term  $D_{V90}$  means that no less than 90% of the particles have a volume mean diameter of  $D_V$ . Similarly  $D_{V50}$  and  $D_{V10}$  means that not less than 50% and 10% respectively have a volume mean diameter of  $D_V$ .

As used herein with reference to particle size, the term "volume mean diameter" ( $D_V$ ) means,

$$D_V = \sqrt[3]{\frac{\sum nD^3}{\sum n}}$$

5 where, n is the number of particles and D is the diameter of the particles, in accordance with, E. L. Parrott., "Milling", Chapter 2, *The Theory and Practice of Industrial Pharmacy*, Ed. Lachman et al., Third Edition, 1986, page 26.

10 Talnetant may be wet-milled in any suitable aqueous, non-aqueous or organic solvent (e.g. an oil). In an embodiment, talnetant is wet-milled in a water-based medium.

Suitable milling apparatus for the preparation of compositions according to the present invention include, conventional wet bead mills such as those manufactured by Nylacast (available from Nylacast Components, 200 Hastings Road, Leicester, LE5 15 OHL, UK), Netzsch (available from Erich NETZSCH GmbH & Co. Holding KG Gebrüder-Netzsch-Straße 19, D-95100 Selb, Germany), Drais (available from Draiswerke, Inc, 40 Whitney Road, Mahwah, NJ 07430, USA) and others. Suitably, the milling chamber of the milling apparatus is lined with or constructed from an abrasion-resistant polymer material. The milling chamber of the milling apparatus may 20 be lined with or constructed from nylon. An example of a suitable milling chamber is described in International Patent Publication WO 02/00196.

Suitable grinding media for use in the preparation of a pharmaceutical composition according to the present invention include glass beads and ceramic beads, for 25 example, those made from rare earth oxide materials. The diameter of said grinding media is for example within the range 0.1 mm to 3 mm, suitably within the range 0.3 mm to 0.8 mm. The density of said grinding media is for example greater than 3 gcm<sup>-3</sup>, suitably within the range 5 to 10 gcm<sup>-3</sup>.

30 Suitable spray drying and spray granulating techniques will be apparent to those skilled in the art (see for example, Gilbert S. Bunker, "Modern Pharmaceutics, Drugs and the Pharmaceutical Sciences", 1996 and references cited therein) and may be effected using a spray dryer, such as the Niro SD 6.3R Spray Dryer (Niro A/S,

Gladsaxevej 305, 2860 Soeborg, Denmark), the Niro Mobile Minor, the Yamato GA-32 Spray Dryer (2-1-6 Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8432, Japan) or a fluid bed granulator, such as the Glatt fluid bed granulator.

- 5 Particles prepared according to the present invention may be sized using conventional techniques known in the art, such as laser light diffraction and photon correlation spectroscopy. A suitable particle sizing apparatus is the Malvern Mastersizer 2000 (available from Malvern Instruments Ltd, Malvern, UK). A further suitable particle sizing apparatus is the Sympatec HELOS (available from Sympatec GmbH, System-Partikel-Technik, Am Pulverhaus 1, D-38678 Clausthal-Zellerfeld, Germany). The Malvern Mastersizer 2000 and the Sympatec HELOS and their operation will be familiar to the skilled person with reference to their operating manuals.
- 10
- 15

In an embodiment, the dispersion contains 5 to 50 % w/w of talnetant. In a further

- embodiment, the dispersion contains 15 to 30 % w/w of talnetant.

The ionic surfactant may be an anionic surfactant or a cationic surfactant. In an embodiment, the ionic surfactant is an anionic surfactant. In a further embodiment, the ionic surfactant is sodium lauryl sulfate or dioctyl sodium sulfosuccinate (docusate sodium). In a still further embodiment the ionic surfactant is sodium lauryl sulfate.

- 20
- 25
- 30

In an embodiment, the concentration of surfactant in the spray dried composition is 0.5 to 3.0% by weight of talnetant. In an embodiment, the concentration of surfactant in the dispersion prior to spray drying is 0.05 to 5.0% by weight of dispersion, in a further embodiment 0.05 to 2.0%.

In an embodiment, the dispersion contains 0.001 to 0.1 moles of ionic surfactant per mole of talnetant. In a further embodiment, the dispersion contains 0.01 to 0.05 moles of surfactant per mole of talnetant.

- 35

In an embodiment the one or more soluble carrier is a soluble sugar. In an embodiment, the one or more soluble carrier is selected from the group consisting of mannitol, sorbitol, lactose, lactitol, xylitol, trehalose, dextrose, sucrose, maltose, fructose, maltitol, xylitol, erythritol, polydextrose, isomalt, cyclodextrin and starch. In a further embodiment, the spray dried composition comprises one or more soluble

carrier selected from the group consisting of mannitol, lactose, erythritol, polydextrose, isomalt and lactitol.

In an embodiment, the concentration of the one or more soluble carrier in the spray

5 dried composition is 10 to 75 % by weight of talnetant. The one or more soluble carrier may be added to the dispersion prior to wet milling. Alternatively, the one or more soluble carrier may be added to the wet milled dispersion before spray drying. In an embodiment, the concentration of the one or more soluble carrier in the dispersion prior to wet milling or after wet milling is 0.1 to 30% by weight of dispersion. In a further

10 embodiment, the concentration of the soluble carrier in the dispersion prior to wet milling or after wet milling is 5 to 15% by weight of dispersion.

In an embodiment, the spray-dried composition comprises one or more anti-agglomeration agents (for example polyvinyl pyrrolidone (PVP) or povidone,

15 hydroxypropyl methyl cellulose and hydroxyethyl cellulose and hydroxypropylcellulose). In an embodiment, the concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant. In an embodiment, the concentration of anti-agglomeration agent in the dispersion prior to spray drying is 0.1 to 10.0% by weight of dispersion, in a further embodiment 0.5 to

20 5.0%.

According to a second aspect, the invention provides a spray dried pharmaceutical composition comprising i) talnetant particles having a  $D_{90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , ii) one or more ionic surfactant and iii) one or more soluble carrier.

25 It will be appreciated that the embodiments described for the first aspect extend to this second aspect.

30 The spray-dried composition and dispersion (prior to wet milling or after wet milling) may contain further suitable pharmaceutically acceptable excipients. Suitable excipients are described in the *Handbook of Pharmaceutical Excipients*, Pharmaceutical Press, 1986, published by The American Pharmaceutical Association and The Royal Pharmaceutical Society of Great Britain. Examples of further excipients include stabilisers to maintain the particles in suspension.

The spray dried composition may be administered to the subject without further processing, however it will generally be formulated into other dosage forms in conjunction with further pharmaceutically acceptable excipients selected with regard to the desired dosage form. These further excipients will typically be added to the spray

5 dried composition after spray drying. Therefore according to a third aspect there is provided a dosage form comprising a composition defined in the second aspect.

It will be appreciated that the embodiments described for the first and second aspects extend to this third aspect.

10

In an embodiment, the dosage form is administered orally. Oral administration will typically involve swallowing so that the compound enters the GIT. Dosage forms for oral administration include solid formulations such as tablets, capsules (containing particulates, powders or non-aqueous suspension), sachets, vials, powders, granules, 15 lozenges, reconstitutable powders and liquid preparations (such as suspensions, emulsions and elixirs).

20

Oral dosage forms may contain further excipients such as binding agents (for example syrup, acacia, gelatin, sorbitol, starch, PVP, HPMC, and tragacanth); fillers (for example lactose, sugar, maize-starch, calcium phosphate, sorbitol and glycine); tabletting lubricants (for example magnesium stearate); and disintegrants (for example starch, crospovidone, croscarmellose sodium, sodium starch glycollate and microcrystalline cellulose). In addition, the oral dosage form may contain preservatives, anti-oxidant, flavours, granulation binders, wetting agents and colorants.

25

In an embodiment, the dosage form for oral administration is a tablet. Tablets may be prepared using standard technology familiar to the formulation scientist, for example by direct compression, granulation, melt congealing and extrusion. The tablet may be coated or uncoated. The tablet may be formulated to be immediate or controlled 30 release. Controlled release formulations include delayed-, sustained-, pulsed- or dual-release. Suitable tabletting excipients are described in the *Handbook of Pharmaceutical Excipients*, Pharmaceutical Press, 1986, published by The American Pharmaceutical Association and The Royal Pharmaceutical Society of Great Britain. Typical tabletting excipients include: carriers [for example microcrystalline cellulose 35 (Avicel PH 102)], lubricating agents (for example magnesium stearate), binding

agents, wetting agents, colorants, flavourings, glidants [for example Colloidal Silicon Dioxide (Cab-O-Sil M-5 P)] and disintegrants [for example crospovidone (Polyplasdone XL)].

5 In a further embodiment the tablet consists of the excipients in composition A of Example 2 hereinafter.

Excipients suitable for preparing liquid dosage forms include: suspending agents (for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, 10 carboxymethylcellulose, aluminium stearate gel and hydrogenated edible fats); emulsifying agents (for example lecithin, sorbitan monooleate and acacia); aqueous or non-aqueous vehicles, which include edible oils (for example almond oil and fractionated coconut oil), oily esters (for example esters of glycerine and propylene glycol), ethyl alcohol, glycerine, water and normal saline; preservatives (for example 15 methyl, propyl p-hydroxybenzoate and sorbic acid); and if desired conventional flavouring or colouring agents.

The effective dose of talnetant depends on the condition of the patient, the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg of 20 talnetant, in an embodiment 30 to 500 mg, in a further embodiment 200 or 400 mg. The unit dose may be administered one or more times per day (for example 2, 3 or 4 times per day). The total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.

25 In an embodiment, the compositions and tablets of the invention are adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.

30 NK<sub>3</sub> receptor antagonists, including talnetant, are useful in the treatment and prevention of a wide variety of clinical diseases and conditions characterised by overstimulation of the NK<sub>3</sub> receptors. These diseases and conditions (hereinafter referred to as "diseases and conditions of the invention") include: CNS disorders such 35 as depression (which term includes bipolar (manic) depression (including type I and

type II), unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features (e.g. lethargy, over-eating/obesity, hypersomnia) or postpartum onset, seasonal affective disorder and dysthymia, depression-related anxiety, psychotic depression,

5 and depressive disorders resulting from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion); anxiety disorders (including generalised anxiety disorder, social anxiety disorder, agitation, tension, social or emotional withdrawal in psychotic patients, panic disorder, and obsessive compulsive disorder); phobias (including agoraphobia and social phobia); psychosis

10 and psychotic disorders (including schizophrenia, schizo-affective disorder, schizopreniform diseases, acute psychosis, alcohol psychosis, autism, delerium, mania (including acute mania), manic depressive psychosis, hallucination, endogenous psychosis, organic psychosyndrome, paranoid and delusional disorders, puerperal psychosis, and psychosis associated with neurodegenerative diseases such

15 as Alzheimer's disease); post-traumatic stress disorder; attention deficit hyperactive disorder; cognitive impairment (e.g. the treatment of impairment of cognitive functions including attention, orientation, memory (memory disorders, amnesia, amnesic disorders and age-associated memory impairment) and language function, and including cognitive impairment as a result of stroke, Alzheimer's disease, Aids-related

20 dementia or other dementia states, as well as other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states)); convulsive disorders such as epilepsy (which includes simple partial seizures, complex partial seizures, secondary generalised seizures, generalised seizures including absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic clonic

25 seizures and atonic seizures); psychosexual dysfunction (including inhibited sexual desire (low libido), inhibited sexual arousal or excitement, orgasm dysfunction, inhibited female orgasm and inhibited male orgasm, hypoactive sexual desire disorder, female sexual desire disorder, and sexual dysfunction side-effects induced by treatment with antidepressants of the SSRI-class); sleep disorders (including

30 disturbances of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy); disorders of eating behaviours (including anorexia nervosa and bulimia nervosa); neurodegenerative diseases (such as alzheimer's disease, amyotrophic lateral sclerosis, motor neuron disease and other motor disorders such as Parkinson's disease (including relief from locomotor deficits and/or motor disability, including slowly

35 increasing disability in purposeful movement, tremors, bradykinesia, hyperkinesia

(moderate and severe), aknesia, rigidity, disturbance of balance and co-ordination, and a disturbance of posture), dementia in Parkinson's disease, dementia in Huntington's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain

5 injury, spinal cord injury or the like, and demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis); withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such activities (such as abuse of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine and phencyclidine-like compounds, opiates such as cannabis, heroin, morphine, sedative,

10 hypnotic, amphetamine or amphetamine-related drugs such as dextroamphetamine, methylamphetamine or a combination thereof); pain (which includes neuropathic pain (including diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; pain associated with fibromyalgia or cancer; AIDS-related and HIV-related neuropathy; chemotherapy-induced neuropathy; neuralgia, such as post-

15 herptic neuralgia and trigeminal neuralgia; sympathetically maintained pain and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions such as rheumatoid arthritis and osteoarthritis; reflex sympathetic dystrophy such as shoulder/hand syndrome), acute pain (e.g. musculoskeletal pain, post operative pain and surgical pain), inflammatory pain and chronic pain, pain associated

20 with normally non-painful sensations such as "pins and needles" (paraesthesia and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in

25 selective sensory pathways (hypoalgesia), pain associated with migraine, and non-cardiac chest pain); certain CNS-mediated disorders (such as emesis, irritable bowel syndrome and non-ulcer dyspepsia); and pulmonary disorders (such as asthma, chronic obstructive pulmonary disease, airway hyperreactivity and cough).

30 More preferred diseases or conditions (hereinafter referred to as "preferred diseases and conditions of the invention") mediated by modulation of the NK<sub>3</sub> receptor are depression; anxiety disorders; phobias; psychosis and psychotic disorders; post-traumatic stress disorder; attention deficit hyperactive disorder; withdrawal from abuse of drugs including smoking cessation or reduction in level or frequency of such

35 activities; irritable bowel syndrome; cognitive impairment; convulsive disorders;

psychosexual dysfunction; sleep disorders; disorders of eating behaviours; neurodegenerative diseases; pain; emesis; irritable bowel syndrome; non-ulcer dyspepsia; and pulmonary disorders (such as asthma, chronic obstructive pulmonary disease, airway hyperreactivity and cough).

5

The following Examples illustrate the present invention.

**Example 1**

**Preparation of spray dried compositions and particle-size recovery after dispersion in 10 water**

a) **Composition 1 (according to the invention)**

Sodium lauryl sulphate (0.3% w/w) and povidone (Kollidone K30) (1.7% w/w) were dissolved in purified water (68.0% w/w). Solid talnetant (20.0% w/w, D<sub>v</sub>90 approximately 20 to 30 µm) was then slowly added with continuous mixing until a 15 homogeneous suspension was obtained. The homogenous suspension was passed through a Netzsch bead mill (containing 85% by volume of yttrium-stabilised 0.3 mm zirconium oxide beads). The dispersion was re-circulated through the bead mill with continual mixing until a D<sub>v</sub>90 of >0.4 µm <1.0 µm was obtained. The D<sub>v</sub>90 was measured using a Malvern Mastersizer 2000. The results are shown in Table 1. 20 Mannitol powder USP (10.0% w/w) was then added to the dispersion until a uniform suspension was obtained. This dispersion was spray-dried using a Niro Mobile Minor spray dryer (operated in accordance with the manufacturers instructions) at the following settings: two-fluid nozzle: 2 bar atomisation pressure; drying gas flowrate: 65 m<sup>3</sup>/hr; suspension spray rate: 35 mL/min; inlet temperature: 150 °C; outlet 25 temperature: 60 °C. A sample of the spray-dried composition was dispersed in water and the D<sub>v</sub>90 was measured using a Malvern Mastersizer 2000. The results are shown in Table 1.

b) **Composition 2 (according to the invention)**

30 Dioctyl sulfosuccinate sodium (30.2 g, 0.3% w/w), povidone (Kollidone K30) (170 g, 1.7% w/w) and mannitol powder USP (1001.9 g, 10.0% w/w) were dissolved in purified water (6820 g, 68.0% w/w). Solid talnetant (2012 g, 20.0% w/w, D<sub>v</sub>90 approximately 20 to 30 µm) was then slowly added with continuous mixing until a homogeneous suspension was obtained. The homogenous suspension was passed through a 35 Netzsch bead mill as described for composition 1. The dispersion was re-circulated

through the bead mill with continual mixing until a  $D_{v90}$  of  $>0.4 \mu\text{m} <1.0 \mu\text{m}$  was obtained. The  $D_{v90}$  was measured using a Malvern Mastersizer 2000. The results are shown in Table 1. This dispersion was spray-dried using a Mobile Minor Niro spray dryer (operated in accordance with the manufacturers instructions) at the following

5 settings: two-fluid nozzle: 2 bar atomisation pressure; suspension spray rate 35 mL/min; inlet temperature: 150 °C; outlet temperature: 60 °C. The spray-dried composition was dispersed in water and the  $D_{v90}$  was measured using a Malvern Mastersizer 2000. The results are shown in Table 1.

10 c) Composition 3 (according to the invention)

Sodium lauryl sulfate (30 g, 0.3% w/w) was dissolved in purified water (6470.3 g, 64.7% w/w). To this stirred solution were slowly added povidone (Kollidone K30) (500.1 g, 5.0% w/w), lactose monohydrate (impalpable #312) (999.7 g, 10.0% w/w) and solid talnetant (2000.5 g, 20.0% w/w,  $D_{v90}$  approximately 20 to 30  $\mu\text{m}$ ) until a 15 homogeneous suspension was obtained. The homogenous suspension was passed through a Netzsch bead mill as described for composition 1. The dispersion was re-circulated with continual mixing until a  $D_{v90}$  of  $>0.4 \mu\text{m} <1.0 \mu\text{m}$  was obtained. The  $D_{v90}$  was measured using a Malvern Mastersizer 2000. The results are shown in Table 1. This dispersion was spray-dried using a Mobile Minor Niro spray dryer 20 (operated in accordance with the manufacturers instructions) at the following settings: two-fluid nozzle: 2 bar atomisation pressure; suspension spray rate: 35 mL/min; inlet temperature: 150 °C; outlet temperature: 60 °C. The spray-dried composition was dispersed in water and the  $D_{v90}$  was measured using a Malvern Mastersizer 2000. The results are shown in Table 1.

25

d) Composition 4 (comparative example – without ionic surfactant and soluble carrier)

Pluronic F68 (a non-ionic surfactant) (3.9% w/w) was added slowly to purified water (74.5 % w/w) followed by solid talnetant (19.6% w/w,  $D_{v90}$  approximately 20 to 30  $\mu\text{m}$ ) 30 with continuous mixing until a homogeneous suspension was obtained. The homogenous suspension was passed through a Netzsch bead mill as described for composition 1. The dispersion was re-circulated through the bead mill with continual mixing until a  $D_{v90}$  of  $>0.4 \mu\text{m} <1.0 \mu\text{m}$  was obtained. The  $D_{v90}$  was measured using a Malvern Mastersizer 2000. The results are shown in Table 1. Povidone (Kollidone K30) (2.0% w/w) was then added to the dispersion until a uniform suspension was 35

obtained. This dispersion was spray-dried using a Niro Mobile Minor spray dryer (operated in accordance with the manufacturers instructions) at the following settings: two-fluid nozzle; 2 bar atomisation pressure; drying gas flowrate: 65 m<sup>3</sup>/hr; suspension spray rate: 35 mL/min; inlet temperature: 110 °C; outlet temperature: 40 °C. A sample 5 of a spray-dried composition was dispersed in water and the D<sub>v</sub>90 was measured using a Malvern Mastersizer 2000. The results are shown in Table 1.

The particle size distribution following redispersion in water for compositions 1 to 4 is shown in Table 1 (the values in parentheses are the corresponding D<sub>v</sub> values of the 10 wet milled suspension before spray drying). The table shows that compositions 1, 2 and 3 gave virtually complete recovery of particle size after redispersion in water, whereas composition 4 gave poor recovery.

Table 1

	Composition 1	Composition 2	Composition 3	Composition 4
D <sub>v</sub> 10 (μm)	0.08 (0.08)	0.08 (0.08)	0.08 (0.07)	0.13 (0.08)
D <sub>v</sub> 50 (μm)	0.18 (0.19)	0.18 (0.19)	0.18 (0.17)	0.55 (0.18)
D <sub>v</sub> 90 (μm)	0.44 (0.49)	0.64 (0.65)	0.59 (0.41)	2.75 (0.41)

15

Example 2

Comparative study to evaluate the effect on pK parameters of oral administration of compositions of talnetant to conscious, male beagle dogs.

A catheter was placed in the cephalic vein of each of four fasted male beagle dogs. 20 Each dog was administered half a Tablet A (the composition of which is shown in Table 2 – the dosage form of the invention). Blood samples were collected via the catheter prior to dosing and at the following times after dosing: 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480, 600 and 1440 minutes. Plasma was prepared and stored frozen for analysis. Plasma concentrations of talnetant (limit of quantitation = 10 25 ng/mL) were quantified by an LC/MS/MS method. Non-compartmental analysis was used for pharmacokinetic analysis of plasma concentration versus actual sampling time data. The dogs were fed at 6 hours post-dose (following the collection of the 6-hour blood sample) and food was removed one hour later.

30 After a wash-out period of one week, the procedure was repeated on the same four dogs with Tablet B. After a further one week wash-out period, the procedure was

repeated with Tablet C, and so on with Tablet D (Tablets B, C and D are comparative examples).

Table 2

Tablet	Constituents (mg/tablet)	Dose (mg/kg)
A	Talnetant <sup>a</sup> (100) Sodium Lauryl Sulfate <sup>a</sup> (1.5) Povidone <sup>a</sup> (8.5) Mannitol <sup>a</sup> (50) Avicel PH 200 <sup>b</sup> (169.4) Crospovidone <sup>b</sup> (38.70) Colloidal Silicon Dioxide <sup>b</sup> (4) Magnesium Stearate <sup>b</sup> (2.9) Opadry yellow <sup>b</sup> (11.25)	5.46 ± 0.60 (n=3)
B	Talnetant <sup>a</sup> (100) Poloxamer <sup>a</sup> 127 (8.5) Povidone <sup>a</sup> (5) Natrosol 250SL <sup>a</sup> (10) Avicel PH 200 <sup>b</sup> (205.9) Crospovidone <sup>b</sup> (38.70) Colloidal Silicon Dioxide <sup>b</sup> (4) Magnesium Stearate <sup>b</sup> (2.9) Opadry yellow <sup>b</sup> (11.25)	5.09 ± 0.66 (n=4)
C	Talnetant <sup>a</sup> (100) Poloxamer 188 <sup>a</sup> (20.03) Povidone <sup>a</sup> (10.01) Avicel PH 200 <sup>b</sup> (199.36) Crospovidone <sup>b</sup> (38.70) Colloidal Silicon Dioxide <sup>b</sup> (4) Magnesium Stearate <sup>b</sup> (2.9) Opadry yellow <sup>b</sup> (11.25)	5.43 ± 0.76 (n=4)
D	Talnetant <sup>a</sup> (100) Poloxamer 188 <sup>a</sup> (10) Povidone <sup>a</sup> (10) Avicel PH 200 <sup>b</sup> (209.4) Crospovidone <sup>b</sup> (38.70) Colloidal Silicon Dioxide <sup>b</sup> (4) Magnesium Stearate <sup>b</sup> (2.9) Opadry yellow <sup>b</sup> (11.25)	5.49 ± 0.68 (n=4)

5

The spray dried compositions used in tablets A, B, C and D were prepared by combining ingredients marked with superscript "a" in similar manner to the methods described in Example 1. Each dispersion was wet-milled to give a  $D_{v90}$  of 0.5  $\mu\text{m}$ .

10 After spray drying, the compositions were tabletted using the ingredients marked with superscript "b" using standard tabletting technology familiar to the skilled person.

The results of the study are shown in Table 3. The results show that administration of Tablet A (the composition of the invention) lead to significant improvement in bioavailability compared with the comparative examples (Tablets B, C and D). In addition the results show that the values for Tablet A were the most consistent among

5 the subjects.

The average relative bioavailability for the three formulations against Tablet C was calculated by determining the relative bioavailability for each animal then calculating the average and standard deviation of the individual relative bioavailability values. Overall,

10 the average relative bioavailability of Table A was  $1.96 \pm 0.34$ , and the individual values were 1.81, 2.35 and 1.72.

$C_{max}$  is the maximum plasma concentration of talnetant achieved.  $T_{max}$  is the time after administration at which the maximum concentration was achieved. AUC is the

15 Area Under the Curve of a plot of plasma concentration against time. AUC(0-t) refers to the area from time zero to the last quantifiable concentration at time t. AUC (0-360) refers to the area from time zero to t = 360 minutes.

Table 3

Tablet	$C_{max}$ ( $\mu\text{g/mL}$ )	$T_{max}$ (min)	AUC (0-360) (min. $\mu\text{g/mL}$ )	AUC (0-t) (min. $\mu\text{g/mL}$ )	Relative Oral Bioavailability $\frac{\text{AUC}(0-360)}{\text{AUC}(0-360)_{\text{Tablet C}}}$
A	$4.04 \pm 0.287$	$521.0 \pm 68.4$	$742.1 \pm 55.0$	$3306.0 \pm 117.2$	$1.96 \pm 0.34$
B	$2.20 \pm 0.796$	$480.0 \pm 0.0$	$345.7 \pm 139.2$	$1373.4 \pm 730.3$	$1.03 \pm 0.23$
C	$2.15 \pm 0.669$	$278.3 \pm 307.5$	$336.8 \pm 121.2$	$1654.0 \pm 1354.8$	$1.00 \pm 0.00$
D	$1.94 \pm 0.850$	$419.8 \pm 206.3$	$305.3 \pm 109.8$	$1391.1 \pm 395.7$	$0.94 \pm 0.27$

4 Pgs Class

Claims

1. A process for the preparation of a spray-dried composition, the composition comprising i) talnetant particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ ,  
5 ii) one or more ionic surfactant and iii) one or more soluble carrier, the process comprising a) wet milling a dispersion of the solid talnetant particles until the  $D_{v90}$  is in the range from 0.1 to 2.0  $\mu\text{m}$ , which dispersion comprises the one or more ionic surfactant and the one or more soluble carrier, then b) spray drying or spray granulating the resulting dispersion.
- 10 2. A process according to claim 1 wherein the dispersion is wet-milled in a water-based medium.
- 15 3. A process according to any preceding claim wherein the dispersion contains 5 to 50 % w/w of talnetant.
4. A process according to any preceding claim wherein the dispersion contains 15 to 30 % w/w of talnetant.
- 20 5. A process according to any preceding claim wherein the ionic surfactant is an anionic surfactant.
6. A process according to any preceding claim wherein the ionic surfactant is sodium lauryl sulfate or dioctyl sodium sulfosuccinate.
- 25 7. A process according to any preceding claim wherein the ionic surfactant is sodium lauryl sulfate.
8. A process according to any preceding claim wherein the concentration of surfactant in the spray dried composition is 0.5 to 3.0% by weight of talnetant.
- 30 9. A process according to any preceding claim wherein the concentration of surfactant in the dispersion prior to spray drying is 0.05 to 5.0% by weight of dispersion.

10. A process according to any preceding claim wherein the dispersion contains 0.001 to 0.1 moles of ionic surfactant per mole of talnetant.
- 5 11. A process according to any preceding claim wherein the one or more soluble carrier is a soluble sugar.
12. A process according to any preceding claim wherein the one or more soluble carrier is selected from the group consisting of mannitol, sorbitol, lactose, lactitol, xylitol, trehalose, dextrose, sucrose, maltose, fructose, maltitol, xylitol, erythritol, polydextrose, isomalt, cyclodextrin and starch.
- 10 13. A process according to any preceding claim wherein the spray dried composition comprises one or more soluble carrier selected from the group consisting of mannitol, lactose, erythritol, polydextrose, isomalt and lactitol.
- 15 14. A process according to any preceding claim wherein the concentration of the one or more soluble carrier in the spray dried composition is 10 to 75 % by weight of talnetant.
- 20 15. A process according to any preceding claim wherein the concentration of the one or more soluble carrier in the dispersion prior to wet milling or after wet milling is 0.1 to 30% by weight of dispersion.
- 25 16. A process according to any preceding claim wherein the spray-dried composition comprises one or more anti-agglomeration agents.
17. A process according to any preceding claim wherein the concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant.
- 30 18. A process according to any preceding claim wherein the concentration of anti-agglomeration agent in the dispersion prior to spray drying is 0.1 to 10.0% by weight of dispersion.

19. A spray dried pharmaceutical composition comprising i) talnetant particles having a  $D_{v90}$  in the range from 0.1 to 2.0  $\mu\text{m}$ , ii) one or more ionic surfactant and iii) one or more soluble carrier.
- 5 20. A pharmaceutical composition according to claim 19 wherein the ionic surfactant is an anionic surfactant.
21. A pharmaceutical composition according to claim 19 or 20 wherein the ionic surfactant is sodium lauryl sulfate or dioctyl sodium sulfosuccinate.
- 10 22. A pharmaceutical composition according to any one of claims 19 to 21 wherein the ionic surfactant is sodium lauryl sulfate.
23. A pharmaceutical composition according to any one of claims 19 to 22 wherein the concentration of surfactant in the spray dried composition is 0.5 to 3.0% by weight of talnetant.
- 15 24. A pharmaceutical composition according to any one of claims 19 to 23 wherein the one or more soluble carrier is a soluble sugar.
- 20 25. A pharmaceutical composition according to any one of claims 19 to 24 wherein the one or more soluble carrier is selected from the group consisting of mannitol, sorbitol, lactose, lactitol, xylitol, trehalose, dextrose, sucrose, maltose, fructose, maltitol, xylitol, erythritol, polydextrose, isomalt, cyclodextrin and starch.
- 25 26. A pharmaceutical composition according to any one of claims 19 to 25 wherein the spray dried composition comprises one or more soluble carrier selected from the group consisting of mannitol, lactose, erythritol, polydextrose, isomalt and lactitol.
- 30 27. A pharmaceutical composition according to any one of claims 19 to 26 wherein the concentration of the one or more soluble carrier in the spray dried composition is 10 to 75 % by weight of talnetant.

28. A pharmaceutical composition according to any one of claims 19 to 27 wherein the spray-dried composition comprises one or more anti-agglomeration agents.
- 5 29. A pharmaceutical composition according to any one of claims 19 to 28 wherein the concentration of the anti-agglomeration agent in the spray-dried composition is 2 to 10% by weight of talnetant.
30. A dosage form comprising a composition defined in any one of claims 19 to 29.
- 10 31. A dosage form according to claim 30 administered orally.
32. A dosage form according to claim 31 administered as a tablet.